Canopy Growth Corp.

 Canopy  Growth Corp.


 Canopy  Growth Corp.

In April 2014, Canopy Growth became the first cannabis company in North America to be publicly traded. We followed that with being the first to complete a “bought deal”, to diversify our platform to include both greenhouse and indoor growing, to acquire a major competitor and to be listed on the Toronto Stock Exchange. Continuing those firsts, we remain the only cannabis company to be a member of a major global stock market index, in this case the S&P/TSX Composite index.

Away from the markets, Tweed, a Canopy Growth subsidiary, was the first to introduce the now standard concept of Compassionate Pricing to make medical cannabis affordable for patients, and we remain proud to continue supporting a patient’s right to grow at home by selling the widest variety of seeds in the legal Canadian sector. Our commitment to education has and always will be unwavering, as one of the first Canadian cannabis companies to offer Mainpro-M1 accredited continuing medical education programs to Canadian doctors, and to launch in-person assistance through our Tweed Main Street locations. Tweed was also the first Canadian producer to be approved to export dried cannabis to Germany, and our wholly-owned German subsidiary continues to offer an ever-wide variety of products for sale through German pharmacies. Most recently, we were the first to strike a strategic relationship with a Fortune 500 beverage alcohol supplier to bring exciting new products to market, and to enter into a ground-breaking supply MOU to sell adult-use Cannabis to a provincial government.

From our cutting edge research at Canopy Health Innovations, to our hemp operations and financing services through Canopy Rivers Corporation, we are proud of our accomplishments, and are always looking for the next first.

Canopy Growth

Canopy Health Innovation

Canopy Health Innovations (CHI) is a cannabis incubator focused on developing and researching clinically ready, whole plant cannabis drug formulations and dose delivery systems. The ultimate goal is to validate diversified treatment options for Canadians and for patients and consumers in other jurisdictions where treatment with cannabis is federally lawful. The foundation of our research and development plan is to improve the quality of life and health of those suffering from acute and chronic illnesses. The proper formulation of cannabinoids have the opportunity to improve a number of common complaints and ailments such as pain, appetite stimulation, and sleep quality. Medical cannabis is also used to manage increasingly common diseases such as Dementia, Alzheimer’s, Autism, Crohn’s Disease and Colitis, and Fibromyalgia. Canopy Animal Health is a wholly-owned subsidiary of Canopy Health, focused on creating cannabis-based healthcare products for companion animals. Our goal is to provide family pets with specialized cannabinoid medicines to maintain, improve or extend their quality of life. Canopy Health has undertaken an extensive intellectual property review which forms the basis of all of our strategic plans.